Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease
- 1 September 1995
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 10 (5) , 604-607
- https://doi.org/10.1002/mds.870100512
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Controlled study of the antiparkinsonian activity and tolerability of cabergolineNeurology, 1993
- Cabergoline: A long‐acting dopamine agonist in Parkinson's diseaseAnnals of Neurology, 1990
- PergolideDrugs, 1990
- Pharmacokinetic and Pharmacodynamic Considerations in Management of Motor Response Fluctuations in Parkinson's DiseaseNeurologic Clinics, 1990
- Pathogenesis of dyskinesias in parkinson's diseaseAnnals of Neurology, 1989
- Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, Part IAnnals of Neurology, 1988
- Long-Lasting Prolactin-Lowering Effect of Cabergoline, A New Dopamine Agonist, in Hyperprolactinemic PatientsJournal of Clinical Endocrinology & Metabolism, 1986